SUI-YUAN CHANGChen M.-Y.Lee C.-N.HSIN-YUN SUNKo W.Chang S.-F.Chang K.-L.SZU-MIN HSIEHWANG-HUEI SHENGLiu W.-C.Wu C.-H.CHUAN-LIANG KAOCHIEN-CHING HUNGSHAN-CHWEN CHANG2020-06-182020-06-1820080305-7453https://scholars.lib.ntu.edu.tw/handle/123456789/503567Objectives: To determine the prevalence and trends of antiretroviral drug resistance among HIV-1-infected Taiwanese patients who have been provided with free-of-charge antiretroviral therapy (ART) since 1990. Methods: Blood samples collected from 786 HIV-1-infected patients from 1999 to 2006 were subjected to genotypic resistance assay. Antiretroviral resistance mutations were identified in accordance with the antiretroviral resistance mutation list of the International AIDS Society-USA Consensus Guidelines. Trends of resistance were studied in patients enrolled in two periods: before (period 1, January 1999 to December 2003) and after (period 2, January 2004 to December 2006) the CRF07_BC outbreak among injection drug users (IDUs). Results: The frequency of HIV-1 isolates harbouring one or more primary mutations associated with antiretroviral resistance to reverse transcriptase inhibitors or protease inhibitors increased significantly from 6.6% in period 1 to 12.7% in period 2 (P = 0.003). A significant increase in prevalence of antiretroviral drug resistance was observed among men who have sex with men and patients infected with HIV subtype B. In multivariate analysis, hepatitis C virus (HCV) exposure, which exhibited collinearity with injection drug use and infection with CRF07_BC, represented a lower risk for infection with resistant viruses. Conclusions: Our findings suggest that the prevalence of antiretroviralresistance has increased in Taiwan over the past 8 years after the introduction of combination ART. IDUs who were HCV-seropositive and infected with CRF07_BC were at lower risk for infection with antiretroviral-resistant viruses. ? The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.[SDGs]SDG3atazanavir; nelfinavir; proteinase inhibitor; RNA directed DNA polymerase inhibitor; adult; antibiotic resistance; article; controlled study; female; hepatitis C; high risk behavior; human; Human immunodeficiency virus 1 infection; Human immunodeficiency virus infected patient; male; male homosexual; medical society; multidrug resistance; mutational analysis; nonhuman; prevalence; superinfection; Taiwan; trend study; virus mutation; virus resistance; Adult; Anti-Retroviral Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Taiwanjournal article10.1093/jac/dkn002182270882-s2.0-40049092925